Evidence map›Paper›PMID 28386661›Full record

ReviewJournal of neuro-oncology2017

The evolving role for re-irradiation in the management of recurrent grade 4 glioma.

Steven P Howard, Andra Krauze, Mike D Chan, Christina Tsien, Wolfgang A Tomé

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Steven P HowardDepartment of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4/350 Clinical Science Center, 600 Highland Avenue, Madison, WI, 53792, USA. howard@humonc.wisc.edu.
Andra KrauzeRadiation Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
Mike D ChanDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Christina TsienDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Wolfgang A ToméDepartment of Radiation Oncology and Department of Neurology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although significant gains have been realized in the management of grade 4 glioma, the majority of these patients will ultimately suffer local recurrence within the prior field of treatment. Clearly, novel local treatment strategies are required to improve patient outcomes. Concerns of toxicity have limited enthusiasm for the utilization of re-irradiation as a treatment option. However, using modern imaging technology and precision radiotherapy delivery techniques re-irradiation has proven a feasible option achieving both a palliative benefit and prolongation of survival with low toxicity rates. The evolution of re-irradiation as a treatment modality for recurrent grade 4 glioma is reviewed. In addition, potential targeted radiosensitizers to be used in conjunction with re-irradiation are also discussed.

Indexed as

Re-IrradiationBrain NeoplasmsGliomaHumansNeoplasm GradingNeoplasm Recurrence, LocalPalliative CareRadiation-Sensitizing AgentsRadiation-Sensitizing AgentsCentral nervous systemRadiosensitizersRecurrent grade 4 gliomaRe-irradiation

Identifiers

PMID28386661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.